Establishment of inducible cAMP early repressor transgenic fibroblasts in a porcine model of human type 1 diabetes mellitus

Molecular Medicine Reports

Volumn 6, Issue 1, 2012, Pages 239-245

  Jung, Eui Man ^a   Kim, Yu Kyung ^b   Lee, Geun Shik ^c   Hyun, Sang Hwan ^a   Hwang, Woo Suk ^b   Jeung, Eui Bae ^a  

^a Chungbuk National University   (South Korea)

^b SooAm Biotech Research Foundation   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

Diabetes mellitus; Fibroblast; Human insulin promoter; Inducible cyclic AMP early repressor I ; Pig

Indexed keywords

INDUCIBLE CYCLIC AMP EARLY REPRESSOR IGAMMA; INSULIN; REPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PROMOTER REGION; PROTEIN EXPRESSION; SWINE; TRANSGENICS;

ANIMALS; CELL LINE; CYCLIC AMP RESPONSE ELEMENT MODULATOR; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FIBROBLASTS; GENE EXPRESSION; GENE ORDER; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; PROMOTER REGIONS, GENETIC; SWINE; TRANSGENES;

RODENTIA; SUIDAE; SUS;

EID: 84861612635     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.895     Document Type: Article

References (44)

1. Mbanya JC and Ramiaya K: Diabetes Mellitus. In: Disease and Mortality in Sub-Saharan Africa. Jamison DT, Feachem RG, Makgoba MW, Bos ER, Baingana FK, Hofman KJ and Rogo KO (eds). World Bank, Washington, DC, pp267-287, 2006.
2. Seelandt KK: Diabetes mellitus update. J Contin Educ Nurs 38: 54-55, 2007.
3. Sander M and German MS: The beta cell transcription factors and development of the pancreas. J Mol Med (Berl) 75: 327-340, 1997. (Pubitemid 27247964)
4. Comb M, Birnberg NC, Seasholtz A, Herbert E and Goodman HM: A cyclic AMP- and phorbol ester-inducible DNA element. Nature 323: 353-356, 1986. (Pubitemid 16033136)
5. Barnett DW, Pressel DM, Chern HT, Scharp DW and Misler S: cAMP-enhancing agents "permit" stimulus-secretion coupling in canine pancreatic islet beta-cells. J Membr Biol 138: 113-120, 1994.
6. Leonard J, Serup P, Gonzalez G, Edlund T and Montminy M: The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells. Proc Natl Acad Sci USA 89: 6247-6251, 1992.
7. Ortmeyer HK: Insulin decreases skeletal muscle cAMP-dependent protein kinase (PKA) activity in normal monkeys and increases PKA activity in insulin-resistant rhesus monkeys. J Basic Clin Physiol Pharmacol 8: 223-235, 1997.
8. Seino S, Takahashi H, Fujimoto W and Shibasaki T: Roles of cAMP signalling in insulin granule exocytosis. Diabetes Obes Metab 11 Suppl 4: 180-188, 2009.
9. Laoide BM, Foulkes NS, Schlotter F and Sassone-Corsi P: The functional versatility of CREM is determined by its modular structure. EMBO J 12: 1179-1191, 1993. (Pubitemid 23095867)
10. Molina CA, Foulkes NS, Lalli E and Sassone-Corsi P: Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 75: 875-886, 1993. (Pubitemid 24014545)
11. Hussain MA, Daniel PB and Habener JF: Glucagon stimulates expression of the inducible cAMP early repressor and suppresses insulin gene expression in pancreatic beta-cells. Diabetes 49: 1681-1690, 2000.
12. Inada A, Yamada Y, Someya Y, et al: Transcriptional repressors are increased in pancreatic islets of type 2 diabetic rats. Biochem Biophys Res Commun 253: 712-718, 1998. (Pubitemid 29039207)
13. Inada A, Someya Y, Yamada Y, et al: The cyclic AMP response element modulator family regulates the insulin gene transcription by interacting with transcription factor IID. J Biol Chem 274: 21095-21103, 1999.
14. Inada A, Hamamoto Y, Tsuura Y, et al: Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic beta cells. Mol Cell Biol 24: 2831-2841, 2004. (Pubitemid 38381273)
15. Saudek F: Gene therapy in the treatment of diabetes mellitus. Cas Lek Cesk 142: 523-527, 2003 (In Czech).
16. Driver JP, Serreze DV and Chen YG: Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol 33: 67-87, 2011.
17. Cheng CK, Hoo RL, Chow BK and Leung PC: Functional cooperation between multiple regulatory elements in the untranslated exon 1 stimulates the basal transcription of the human GnRH-II gene. Mol Endocrinol 17: 1175-1191, 2003. (Pubitemid 36819943)
18. Lee GS, Choi KC, Han HJ and Jeung EB: The classical and a non-classical pathways associated with NF-kappaB are involved in estrogen-mediated regulation of calbindin-D9k gene in rat pituitary cells. Mol Cell Endocrinol 277: 42-50, 2007.
19. Inada A, Nagai K, Arai H, et al: Establishment of a diabetic mouse model with progressive diabetic nephropathy. Am J Pathol 167: 327-336, 2005. (Pubitemid 43026090)
20. Fridlyand LE and Philipson LH: Reactive species, cellular repair and risk factors in the onset of type 2 diabetes mellitus: review and hypothesis. Curr Diabetes Rev 2: 241-259, 2006. (Pubitemid 44082943)
21. Aszalos Z: Cerebral complications of diabetes mellitus. Orv Hetil 148: 2371-2376, 2007 (In Hungarian).
22. Odagiri H, Wang J and German MS: Function of the human insulin promoter in primary cultured islet cells. J Biol Chem 271: 1909-1915, 1996. (Pubitemid 26047770)
23. Burkhardt BR, Loiler SA, Anderson JA, et al: Glucose-responsive expression of the human insulin promoter in HepG2 human hepatoma cells. Ann N Y Acad Sci 1005: 237-241, 2003. (Pubitemid 38507762)
24. Nakasone H, Kako S, Endo H, et al: Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia. Hematology 14: 361-365, 2009.
25. Nosadini R, Crepaldi G and D'Angelo A: Diabetes mellitus and hypertension: a physiologic basis for a rational therapeutic approach. Am Heart J 121: 1289-1293, 1991.
26. Siraj ES, Seyoum B, Saenz C and Abdulkadir J: Lipid and lipoprotein profiles in Ethiopian patients with diabetes mellitus. Metabolism 55: 706-710, 2006.
27. Karic E, Tulumovic D, Ramic E, Zildzic M and Tulumovic A: Evaluation of diabetic nephropathy in older patients with diabetes mellitus type 2. Med Arh 62: 261-263, 2008.
28. Yargicoglu P, Agar A, Edremitlioglu M, Oguz Y and Apaydin C: The effect of cadmium on visual evoked potentials in alloxane-induced diabetic rats: relation to lipid peroxidation. Acta Diabetol 36: 197-204, 1999.
29. Rerup CC: Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 22: 485-518, 1970.
30. Wu D, Zou C, Yue F, Li X, Li S and Zhang YA: The effect of long-term streptozotocin-induced diabetes mellitus (STZ-DM) on cynomolgus (Macaca fascicularis) monkeys. J Med Primatol 38: 15-22, 2009.
31. Sugioka N, Sato K, Haraya K, et al: Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. Biopharm Drug Dispos 29: 469-479, 2008.
32. Li M, Inaba M, Guo KQ, Hisha H, Abraham NG and Ikehara S: Treatment of streptozotocin-induced diabetes mellitus in mice by intra-bone marrow bone marrow transplantation plus portal vein injection of beta cells induced from bone marrow cells. Int J Hematol 86: 438-445, 2007.
33. Hartoft-Nielsen ML, Rasmussen AK, Bock T, Feldt-Rasmussen U, Kaas A and Buschard K: Iodine and tri-iodo-thyronine reduce the incidence of type 1 diabetes mellitus in the autoimmune prone BB rats. Autoimmunity 42: 131-138, 2009.
34. Tirabassi RS, Flanagan JF, Wu T, Kislauskis EH, Birckbichler PJ and Guberski DL: The BBZDR/Wor rat model for investigating the complications of type 2 diabetes mellitus. ILAR J 45: 292-302, 2004.
35. Zella JB, McCary LC and DeLuca HF: Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 417: 77-80, 2003. (Pubitemid 36960051)
36. Pedotti R, Sanna M, Tsai M, et al: Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol 4: 2, 2003.
37. Corsetti JP, Sparks JD, Peterson RG, Smith RL and Sparks CE: Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 148: 231-241, 2000. (Pubitemid 30064454)
38. Burgdorf C, Hansel L, Heidbreder M, et al: Suppression of cardiac phosphatidate phosphohydrolase 1 activity and lipin mRNA expression in Zucker diabetic fatty rats and humans with type 2 diabetes mellitus. Biochem Biophys Res Commun 390: 165-170, 2009.
39. Bajotto G, Murakami T, Nagasaki M, Sato Y and Shimomura Y: Decreased enzyme activity and contents of hepatic branched-chain alpha-keto acid dehydrogenase complex subunits in a rat model for type 2 diabetes mellitus. Metabolism 58: 1489-1495, 2009.
40. Noguchi S, Ohno Y and Aoki N: Adrenocortical insufficiency in Otsuka Long-Evans Tokushima Fatty rats, a type 2 diabetes mellitus model. Metabolism 56: 1326-1333, 2007. (Pubitemid 47404594)
41. Howarth FC, Shafiullah M and Qureshi MA: Chronic effects of type 2 diabetes mellitus on cardiac muscle contraction in the Goto-Kakizaki rat. Exp Physiol 92: 1029-1036, 2007. (Pubitemid 47568843)
42. Phillips AO, Baboolal K, Riley S, et al: Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. Am J Kidney Dis 37: 400-410, 2001. (Pubitemid 32116034)
43. Mauvais-Jarvis F and Kahn CR: Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: what can we learn from transgenic and knockout mice? Diabetes Metab 26: 433-448, 2000. (Pubitemid 32101815)
44. Ristow M: Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl) 82: 510-529, 2004.